Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cachet Pharmaceutical Co., Ltd. (002462.SZ)
CNY11.85
+0.29 (+2.51%)
CN SHZ Healthcare Medical - Pharmaceuticals
Address
Building 1 100195
Beijing, CN
Beijing, CN
CEO
Yibin Huang
Website
cachet.com.cn
IPO
2010-08-18
ISIN CNE100000SN0
Description
Established in Beijing, China, in 1998, Cachet Pharmaceutical Co., Ltd. is a prominent Chinese enterprise engaged in the comprehensive wholesale and retail trade of pharmaceutical goods. The company's operations are multifaceted, encompassing the provision of medicines to hospitals, the large-scale distribution of biological products, medical devices, and traditional Chinese remedies. Additionally, it handles pharmaceutical logistics and actively manufactures its own line of medications. In Beijing, Cachet Pharmaceutical maintains a significant retail footprint with 150 chain stores, where customers can find a wide array of products, including pharmaceuticals, health supplements, medical instruments, cosmetics, daily essentials, and traditional Chinese medicines.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY11.85
+0.29 (+2.51%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.37
Float Shares
242.68M
Free Float %
83.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.01% | +2.08% | -1.72% | -12.32% | -10.20% | -4.39% | +1.18% | -8.41% | -6.15% | -59.99% | -2.42% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11.85
DCF (Unlevered)
29.97
+152.9%
DCF (Levered)
33.56
+183.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.89
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%-18.7% Q1'26: -15.1% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-30.9% Q1'26: -18.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+4.7% Q1'26: -5.3% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+1.9% Q1'26: +2.5% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.2% Q1'26: +5.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.3% Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×4.03× ★ Q1'26: 4.38× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.20B
est: 8.39B (-2.2%)
|
10.97B
est: 10.77B (+1.9%)
|
14.24B
est: 14.25B (-0.1%)
|
17.96B
est: 18.05B (-0.5%)
|
22.19B
est: 21.85B (+1.5%)
|
23.26B
est: 28.47B (-18.3%)
|
25.63B
est: 30.95B (-17.2%)
|
24.02B
est: 10.77B (+123.0%)
|
19.53B
est: 14.25B (+37.0%)
|
18.05B
18.05B – 18.05B
+26.7% YoY
|
21.85B
21.85B – 21.85B
+21.0% YoY
|
28.47B
28.47B – 28.47B
+30.3% YoY
|
30.95B
30.95B – 30.95B
+8.7% YoY
|
30.95B
30.95B – 30.95B
+0.0% YoY
|
| EBITDA |
511.32M
est: 330.33M (+54.8%)
|
663.22M
est: 424.16M (+56.4%)
|
773.20M
est: 561.25M (+37.8%)
|
1.00B
est: 710.98M (+41.3%)
|
1.17B
est: 860.54M (+36.2%)
|
1.14B
est: 1.12B (+1.5%)
|
1.13B
est: 1.22B (-7.4%)
|
740.25M
est: 355.21M (+108.4%)
|
447.95M
est: 470.01M (-4.7%)
|
595.40M
595.40M – 595.40M
+26.7% YoY
|
720.64M
720.64M – 720.64M
+21.0% YoY
|
939.05M
939.05M – 939.05M
+30.3% YoY
|
1.02B
1.02B – 1.02B
+8.7% YoY
|
1.02B
1.02B – 1.02B
+0.0% YoY
|
| EBIT |
486.09M
est: 268.38M (+81.1%)
|
635.49M
est: 344.62M (+84.4%)
|
742.83M
est: 456.00M (+62.9%)
|
972.15M
est: 577.65M (+68.3%)
|
1.09B
est: 699.16M (+56.1%)
|
1.01B
est: 911.05M (+10.9%)
|
988.22M
est: 990.38M (-0.2%)
|
688.89M
est: 306.63M (+124.7%)
|
360.69M
est: 405.73M (-11.1%)
|
513.97M
513.97M – 513.97M
+26.7% YoY
|
622.09M
622.09M – 622.09M
+21.0% YoY
|
810.62M
810.62M – 810.62M
+30.3% YoY
|
881.21M
881.21M – 881.21M
+8.7% YoY
|
881.21M
881.21M – 881.21M
+0.0% YoY
|
| Net Income |
172.98M
est: 219.32M (-21.1%)
|
223.10M
est: 270.45M (-17.5%)
|
263.64M
est: 335.00M (-21.3%)
|
327.63M
est: 391.20M (-16.2%)
|
375.96M
est: 470.32M (-20.1%)
|
317.59M
est: 595.93M (-46.7%)
|
353.88M
est: 674.81M (-47.6%)
|
160.67M
est: 271.36M (-40.8%)
|
111.38M
est: 336.12M (-66.9%)
|
392.50M
392.50M – 392.50M
+16.8% YoY
|
471.89M
471.89M – 471.89M
+20.2% YoY
|
597.93M
597.93M – 597.93M
+26.7% YoY
|
677.07M
677.07M – 677.07M
+13.2% YoY
|
677.07M
677.07M – 677.07M
+0.0% YoY
|
| SGA |
515.82M
est: 255.85M (+101.6%)
|
509.11M
est: 328.53M (+55.0%)
|
588.03M
est: 434.71M (+35.3%)
|
818.37M
est: 550.68M (+48.6%)
|
1.12B
est: 666.52M (+68.0%)
|
907.99M
est: 868.51M (+4.5%)
|
1.08B
est: 944.14M (+13.9%)
|
882.78M
est: 347.36M (+154.1%)
|
81.17M
est: 459.63M (-82.3%)
|
582.25M
582.25M – 582.25M
+26.7% YoY
|
704.73M
704.73M – 704.73M
+21.0% YoY
|
918.31M
918.31M – 918.31M
+30.3% YoY
|
998.27M
998.27M – 998.27M
+8.7% YoY
|
998.27M
998.27M – 998.27M
+0.0% YoY
|
| EPS |
0.72
est: 0.75 (-4.1%)
|
0.89
est: 0.93 (-3.9%)
|
1.05
est: 1.15 (-8.4%)
|
1.31
est: 1.34 (-2.2%)
|
1.44
est: 1.61 (-10.6%)
|
1.09
est: 2.04 (-46.6%)
|
1.21
est: 2.31 (-47.6%)
|
0.55
est: 0.93 (-40.6%)
|
0.38
est: 1.15 (-66.9%)
|
1.34
1.34 – 1.34
+16.8% YoY
|
1.61
1.61 – 1.61
+20.2% YoY
|
2.04
2.04 – 2.04
+26.7% YoY
|
2.31
2.31 – 2.31
+13.2% YoY
|
2.31
2.31 – 2.31
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
573.28M
OE per share TTM
1.96
Owner's Yield
14.25%
Maintenance CapEx ratio
51.97%
Maint CapEx / Avg PPE
2.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 10 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 10.3K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.6K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 509.5K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 818.60 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.5K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.3K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 583.91 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 67.44 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 22.16 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 10.56 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
153.0K
Shares Outstanding
291.71M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao Chai | Assistant to the President & Board Secretary | — | male |
| Jiang Wang | Secretary of the Discipline Inspection Commission | — | male |
| Jun Lin | VP & Accounting Supervisor | — | male |
| Wang Peng | Vice President | — | male |
| Yibin Huang | President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002462.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
